|
|
Saturday, October 11, 2025 | Multitumor Symposium | Orlando, Florida
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology CareA Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Date and Time
Saturday, October 11, 2025 7:15 AM – 12:30 PM (eastern time) Breakfast and lunch buffet sponsored by FCS Location The Ritz-Carlton Orlando, Grande Lakes 4012 Central Florida Parkway Orlando, Florida Hotel Phone: (407) 206-2400 Meeting Room Tuscany Ballroom (Salons D-H) — Lobby Level
Breast Cancer
Harold J Burstein, MD, PhD Director of Academic Partnerships Institute Physician Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School Boston, Massachusetts Matthew P Goetz, MD Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD Professor of Oncology and Pharmacology Department of Oncology Mayo Clinic Rochester, Minnesota Heather McArthur, MD, MPH, FASCO Professor, Department of Internal Medicine Komen Distinguished Chair in Clinical Breast Cancer Research UT Southwestern Medical Center Dallas, Texas Additional faculty to be announced. Colorectal Cancer Christopher Lieu, MD Professor of Medicine Associate Director for Clinical Research Director, GI Medical Oncology University of Colorado Cancer Center Aurora, Colorado John Strickler, MD Professor of Medicine Associate Director, Clinical Research – GI Co-Leader, Molecular Tumor Board Duke University Durham, North Carolina Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Matthew Lunning, DO Professor Medical Director Gene and Cellular Therapy Associate Vice Chair of Research Department of Medicine Assistant Vice Chancellor for Clinical Research Fred and Pamela Buffett Cancer Center University of Nebraska Medical Center Omaha, Nebraska Sonali M Smith, MD Elwood V Jensen Professor of Medicine Chief, Section of Hematology/Oncology Co-Leader, Cancer Service Line The University of Chicago Chicago, Illinois
Prostate Cancer
Emmanuel S Antonarakis, MD Clark Endowed Professor of Medicine Division of Hematology, Oncology and Transplantation University of Minnesota Minneapolis, Minnesota Additional faculty to be announced. Moderator Neil Love, MD Research To Practice Miami, Florida Join us on Saturday, October 11th from 7:15 AM to 12:30 PM eastern time for this multitumor CME/MOC-, NCPD- and ACPE-accredited event. A detailed agenda will be announced in the coming weeks. Target Audience Learning Objectives CME, ABIM MOC, ABS and ACPE credit information will be given to each participant as part of the meeting course materials. NCPD Credit To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials. CME Accreditation Statement Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME Credit Designation Statement Research To Practice designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology. American Board of Surgery (ABS) — Continuous Certification (CC) Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 5 Medical Knowledge MOC points toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit. Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology. NCPD Accreditation Statement Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). NCPD Credit Designation Statements This educational activity for 5 contact hours is provided by Research To Practice. This activity is awarded 5 ANCC pharmacotherapeutic contact hours. Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information This activity will be remitted for ONCC/ILNA approval. ACPE Accreditation Statement The University of Texas at Austin College of Pharmacy Continuing Education provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. ACPE Credit Designation Statement This activity is approved for up to 0.05 CEU (5 contact hours) of continuing education credit. To receive 5 contact hours of CE credit, the participant must attend each session and complete the online evaluation. Upon successful completion of the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3 to 4 weeks for processing). Privacy Policy Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. Unlabeled/Unapproved Uses Notice This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors. There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified. Content Validation and Disclosures Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of a CME/NCPD/ACPE-accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer (physician for CME, nurse for NCPD) for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Antonarakis — Advisory Committees: Bayer HealthCare Pharmaceuticals, DAVA Oncology, EcoR1 Capital LLC, Janssen Biotech Inc, Johnson & Johnson, Lilly, Merck, Pfizer Inc, Tango Therapeutics, Tempus, Z-Alpha; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, MacroGenics Inc, Merck, Novartis, Orion Corporation, pharmaand GmbH, Seagen Inc; Honoraria: ClearView Healthcare Partners, Curium, Lilly, Merck; Nonrelevant Financial Relationships: Fred Hutch Cancer Center, The Medical Educator Consortium. Dr Goetz — Advisory Committees (to Mayo Clinic): AstraZeneca Pharmaceuticals LP, BeOne, Biotheranostics Inc, Biotheryx, EcoR1 Capital LLC, Genentech, a member of the Roche Group, Incyclix Bio, Laekna Therapeutics, Novartis, Rna Diagnostics, Sermonix Pharmaceuticals, TerSera Therapeutics LLC; Consulting Agreements (to Mayo Clinic): Lilly, Novartis, Stemline Therapeutics; Contracted Research (to Mayo Clinic): AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Biotheryx, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Sermonix Pharmaceuticals, SimBioSys; Data and Safety Monitoring Boards/Committees (to Mayo Clinic): Pfizer Inc; Personal Fees for CME Activities: DAVA Oncology; Travel Support: Lilly; Nonrelevant Financial Relationships: AXIS Medical Education Inc, BroadcastMed, IDEOlogy Health, MJH Life Sciences, PeerView, Physician Education Resource (PER), Total Health Conferencing. Dr Lieu — Consulting Agreements (to Institution): Pfizer Inc; Contracted Research (All to Institution): Genentech, a member of the Roche Group, Janssen Biotech Inc, Sanofi. Dr Lunning — Consulting/Honoraria: AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Pfizer Inc, Recordati, Regeneron Pharmaceuticals Inc, Seagen Inc, Veeva, Vittoria Biotherapeutics; Research Funding: AbbVie Inc, Bristol Myers Squibb, Fate Therapeutics, Kite, A Gilead Company. Dr McArthur — Advisory Committees: AstraZeneca Pharmaceuticals LP, ALX Oncology, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc; Contracted Research (to Institution): AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck. Dr Smith — Consulting Agreements: Foresight Diagnostics, Genmab US Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Celgene Corporation, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc. Dr Strickler — Advisory Committees: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cytovation ASA, Daiichi Sankyo Inc, GE Healthcare, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Leap Therapeutics Inc, Lilly, Merck, Natera Inc, Pfizer Inc, Pheon Therapeutics, Quanta Therapeutics, Regeneron Pharmaceuticals Inc, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Triumvira Immunologics, Xilio Therapeutics; Contracted Research: AbbVie Inc, Amgen Inc, Apollo Therapeutics, Bayer HealthCare Pharmaceuticals, BeOne, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Leap Therapeutics Inc, Lilly, Novartis, Pfizer Inc, Quanta Therapeutics, Revolution Medicines; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Johnson & Johnson; Stock Options — Private Companies: Triumvira Immunologics. Additional faculty to be announced. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.Research To Practice CME/NCPD/ACPE Planning Committee Members, Staff and Reviewers Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
The Ritz-Carlton Orlando, Grande Lakes
4012 Central Florida Parkway Orlando, FL 32837 Hotel Phone: (407) 206-2400 Meeting Room Tuscany Ballroom (Salons D-H) — Lobby Level Hotel Room Reservations
Map:
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.
At this time in-person registration for this educational activity is limited to practicing clinicians. For all other professionals,* we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by choosing the second registration option below. Should seats become available for the program, we will notify you. Registration to attend virtually is open to all professionals. There is no registration fee for this event. Preregistration is advised for the in-person program in Orlando as seating is limited. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians » STANDBY IN-PERSON Registration for other/industry professionals*
If you would like to stand by for participation in this event, please provide your contact information here. We will notify you if seats become available. STANDBY IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. |